Published in Arzneimittelforschung on January 01, 2004
In vivo evaluation of the antiviral activity of Cajanus cajan on measles virus. Arch Virol (2011) 0.95
Utilization of the embryonated egg for in vivo evaluation of the anti-influenza virus activity of neuraminidase inhibitors. Med Microbiol Immunol (2005) 0.77
Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med (2011) 4.46
Prevalence of PB1-F2 of influenza A viruses. J Gen Virol (2007) 1.88
Varicella vaccination in Europe - taking the practical approach. BMC Med (2009) 1.63
Phylogenetics, evolution, and medical importance of polyomaviruses. Infect Genet Evol (2009) 1.46
The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies. Vaccine (2011) 1.35
Sequencing of porcine enterovirus groups II and III reveals unique features of both virus groups. J Virol (2002) 1.34
Novel [(biphenyloxy)propyl]isoxazole derivatives for inhibition of human rhinovirus 2 and coxsackievirus B3 replication. J Antimicrob Chemother (2005) 1.32
High prevalence of amantadine resistance among circulating European porcine influenza A viruses. J Gen Virol (2009) 1.30
Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis (2008) 1.28
Prevalence of hepatitis E virus-specific antibodies in humans with occupational exposure to pigs. Med Microbiol Immunol (2011) 1.28
Sequencing of 21 varicella-zoster virus genomes reveals two novel genotypes and evidence of recombination. J Virol (2011) 1.16
Distribution of varicella-zoster virus (VZV) wild-type genotypes in northern and southern Europe: evidence for high conservation of circulating genotypes. Virology (2008) 1.13
Current knowledge on PB1-F2 of influenza A viruses. Med Microbiol Immunol (2010) 1.12
Novel reassortant of swine influenza H1N2 virus in Germany. J Gen Virol (2008) 1.12
Molecular-based reclassification of the bovine enteroviruses. J Gen Virol (2006) 1.10
Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res (2004) 1.09
The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model. Value Health (2007) 1.08
Acyclovir resistance in herpes simplex encephalitis. Ann Neurol (2010) 1.06
Primary versus secondary failure after varicella vaccination: implications for interval between 2 doses. Pediatr Infect Dis J (2013) 1.04
Evolution and world-wide distribution of varicella-zoster virus clades. Infect Genet Evol (2010) 1.04
European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus. J Clin Virol (2006) 1.03
Isolation and molecular characterization of a second serotype of the encephalomyocarditis virus. Vet Microbiol (2012) 1.02
Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster. J Clin Microbiol (2004) 1.02
Quantitative structure-activity relationship studies of [(biphenyloxy)propyl]isoxazole derivatives. Inhibitors of human rhinovirus 2 replication. J Med Chem (2007) 1.02
Antiviral potential and molecular insight into neuraminidase inhibiting diarylheptanoids from Alpinia katsumadai. J Med Chem (2010) 1.01
Structure-based virtual screening for the discovery of natural inhibitors for human rhinovirus coat protein. J Med Chem (2008) 1.01
Determinants of the recognition of enteroviral cloverleaf RNA by coxsackievirus B3 proteinase 3C. RNA (2002) 1.01
The burden of varicella in Germany. Potential risks and economic impact. Eur J Health Econ (2004) 1.00
Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol (2008) 1.00
Per aspera ad astra: application of Simplex QSAR approach in antiviral research. Future Med Chem (2010) 0.98
Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001. Intervirology (2006) 0.98
Susceptibility of coxsackievirus B3 laboratory strains and clinical isolates to the capsid function inhibitor pleconaril: antiviral studies with virus chimeras demonstrate the crucial role of amino acid 1092 in treatment. J Antimicrob Chemother (2005) 0.97
Prevalence of BK virus subtype I in Germany. J Med Virol (2006) 0.97
Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test. Clin Vaccine Immunol (2012) 0.96
Evolution of four BK virus subtypes. Infect Genet Evol (2008) 0.95
Prevalence of antibodies to European porcine influenza viruses in humans living in high pig density areas of Germany. Med Microbiol Immunol (2013) 0.95
Reassortants of the pandemic (H1N1) 2009 virus and establishment of a novel porcine H1N2 influenza virus, lineage in Germany. Vet Microbiol (2013) 0.94
Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ (2014) 0.94
Influenza A virus PB1-F2 gene. Emerg Infect Dis (2006) 0.93
Prevalence of influenza A and B antibodies in pregnant women and their offspring. J Clin Virol (2009) 0.93
Herpes zoster by reactivated vaccine varicella zoster virus in a healthy child. Eur J Pediatr (2002) 0.92
Comparative analysis of DNA breakage, chromosomal aberrations and apoptosis induced by the anti-herpes purine nucleoside analogues aciclovir, ganciclovir and penciclovir. Mutat Res (2002) 0.91
N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells. J Virol (2006) 0.91
Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res (2003) 0.90
The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis (2014) 0.90
Seroprevalence of hepatitis E virus (HEV) in humans living in high pig density areas of Germany. Med Microbiol Immunol (2014) 0.90
Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther (2011) 0.90
Interferon-gamma-induced activation of nitric oxide-mediated antiviral activity of macrophages caused by a recombinant coxsackievirus B3. Viral Immunol (2005) 0.89
Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006. Antiviral Res (2009) 0.88
Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med Microbiol Immunol (2003) 0.88
Influenza vaccination coverage rates in Germany a population-based cross-sectional analysis of the seasons 2002/2003 and 2003/2004. Med Klin (Munich) (2005) 0.87
Antibody-dependent enhancement of coxsackievirus B3 infection of primary CD19+ B lymphocytes. Viral Immunol (2010) 0.87
Poly(rC)-binding protein 2 interacts with the oligo(rC) tract of coxsackievirus B3. Biochem Biophys Res Commun (2007) 0.86
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008. Med Microbiol Immunol (2011) 0.86
Characterization of a novel picornavirus isolate from a diseased European eel (Anguilla anguilla). J Virol (2013) 0.86
Interface dynamics explain assembly dependency of influenza neuraminidase catalytic activity. J Biomol Struct Dyn (2013) 0.86
Anti-coxsackievirus B3 activity of 2-amino-3-nitropyrazolo[1,5-a]pyrimidines and their analogs. Bioorg Med Chem Lett (2005) 0.85
Direct interferon-gamma-mediated protection caused by a recombinant coxsackievirus B3. Virology (2003) 0.85
Swine influenza A vaccines, pandemic (H1N1) 2009 virus, and cross-reactivity. Emerg Infect Dis (2010) 0.85
Ongoing evolution of swine influenza viruses: a novel reassortant. Arch Virol (2008) 0.85
Age-related and regional differences in the prevalence of hepatitis E virus-specific antibodies in pigs in Germany. Vet Microbiol (2013) 0.85
New pleconaril and [(biphenyloxy)propyl]isoxazole derivatives with substitutions in the central ring exhibit antiviral activity against pleconaril-resistant coxsackievirus B3. Antiviral Res (2008) 0.84
Linkage map of protein-protein interactions of Porcine teschovirus. J Gen Virol (2005) 0.84
Antiviral effects of pan-caspase inhibitors on the replication of coxsackievirus B3. Apoptosis (2007) 0.84
Prevalence of antibodies to swine influenza viruses in humans with occupational exposure to pigs, Thuringia, Germany, 2008-2009. J Med Virol (2010) 0.84
Serological detection of specific IgG to varicella-zoster virus by novel ELISA based on viral glycoprotein antigen. Clin Lab (2009) 0.83
Virus isolate from carp: genetic characterization reveals a novel picornavirus with two aphthovirus 2A-like sequences. J Gen Virol (2014) 0.83
Low level myocardial parvovirus B19 persistence is a frequent finding in patients with heart disease but unrelated to ongoing myocardial injury. J Med Virol (2010) 0.83
Efficacy of influenza vaccination and tamiflu® treatment--comparative studies with Eurasian Swine influenza viruses in pigs. PLoS One (2013) 0.83
Universal mass vaccination against varicella in Germany using an MMRV combination vaccine with a two-dose schedule: an economic analysis. Vaccine (2007) 0.83
Genotyping of varicella-zoster virus strains after serial passages in cell culture. J Virol Methods (2007) 0.83
Frequent detection of parvovirus B19 genome in the myocardium of adult patients with idiopathic dilated cardiomyopathy. Med Microbiol Immunol (2003) 0.83
Fatal outcome of herpes simplex virus type 1-induced necrotic hepatitis in a neonate. Med Microbiol Immunol (2006) 0.82
Enhancing sensitivity of human herpes virus diagnosis with DNA microarrays using dendrimers. Exp Mol Pathol (2004) 0.82
Inhibition of fatty acid synthase by amentoflavone reduces coxsackievirus B3 replication. Arch Virol (2011) 0.82
Detection of multiple human herpes viruses by DNA microarray technology. Mol Diagn (2004) 0.82
Simvastatin treatment showed no prophylactic effect in influenza virus-infected mice. J Med Virol (2013) 0.82
Resistance testing of clinical varicella-zoster virus strains. Antiviral Res (2011) 0.82
Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res (2003) 0.82
Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antivir Ther (2011) 0.82
Apoptosis induced by (E)-5-(2-bromovinyl)-2'-deoxyuridine in varicella zoster virus thymidine kinase-expressing cells is driven by activation of c-Jun/activator protein-1 and Fas ligand/caspase-8. Mol Pharmacol (2003) 0.81
Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients. Med Microbiol Immunol (2012) 0.81
Vaccination procedures against Coxsackievirus-induced heart disease. Expert Rev Vaccines (2003) 0.81
Varicella outbreak in Indian students in Magdeburg with detection of the African-Indian VZV clade 5. J Dtsch Dermatol Ges (2010) 0.81
Impact of global warming on viral diseases: what is the evidence? Curr Opin Biotechnol (2008) 0.81
Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antiviral Res (2012) 0.81
Co-expression of interleukin-2 by a bicistronic plasmid increases the efficacy of DNA immunization to prevent influenza virus infections. Intervirology (2006) 0.81
Novel recombinant ELISA assays for determination of type-specific IgG antibodies against HSV-1 and HSV-2. J Virol Methods (2007) 0.80
Neuraminidase inhibitor susceptibility of porcine H3N2 influenza A viruses isolated in Germany between 1982 and 1999. Antiviral Res (2007) 0.80
QSAR analysis of [(biphenyloxy)propyl]isoxazoles: agents against coxsackievirus B3. Future Med Chem (2011) 0.80
Analysis of varicella-zoster virus and herpes simplex virus in various clinical samples by the use of different PCR assays. J Virol Methods (2009) 0.80